文献速递妇科产科

Sapanisertib与Serabelisib双靶向PI3K/mTOR联合紫杉醇治疗晚期实体瘤的I期剂量递增研究

Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
PubMed 文献 · Gynecol Oncol · 2022-07-15

这项开放标签队列I期试验采用传统3+3剂量递增设计,纳入19例经治晚期实体瘤患者(卵巢癌10例、乳腺癌3例、子宫内膜癌6例),评估Sapanisertib、Serabelisib联合每周紫杉醇的安全性与疗效,确定RP2D,15例可评估患者ORR为47%、CBR为73%。

要点

  • RP2D为Sapanisertib 3或4 mg、Serabelisib 200 mg于第2-4、9-11、16-18、23-25天给药,联合紫杉醇80 mg/m2于第1、8、15天给药,每28天为一周期。
  • 15例可评估患者中ORR为47%、CBR为73%;全部19例中PFS为11个月,OS在17个月时仍在随访中。
  • 最常见3或4级不良事件为白细胞减少(20%)、非发热性中性粒细胞减少(12%)、贫血(9%)、肝酶升高(4%)和高血糖(11%)。

核心结论

  • Sapanisertib、Serabelisib联合紫杉醇方案安全且总体耐受良好,在存在未满足需求的领域初步疗效显著,尤其在PI3K/AKT/mTOR通路异常患者中。
  • 对铂类难治且紫杉类、依维莫司或替西罗莫司治疗失败的患者仍可见积极效应和持续临床获益。

研究设计与样本

  • 开放标签队列I期试验,采用传统3+3剂量递增设计,共5个剂量队列。
  • 纳入19例经治晚期实体瘤患者(卵巢癌10例、乳腺癌3例、子宫内膜癌6例),所有患者入组前均接受全面基因组分析。

主要发现

  • 15例可评估患者中ORR为47%,CBR为73%。
  • 3例达完全缓解(CR),4例达部分缓解(PR),4例疾病稳定(SD)超过6个月。
  • 全部19例入组患者中,PFS为11个月,OS在17个月时仍在随访中。
  • 第5队列所有患者均需减量,其中1例发生剂量限制性毒性(DLT)。
  • 最常见3或4级不良事件为白细胞减少(20%)、非发热性中性粒细胞减少(12%)、贫血(9%)、肝酶升高(4%)和高血糖(11%)。

关键数值与推荐

  • RP2D为Sapanisertib 3或4 mg,Serabelisib 200 mg于第2-4、9-11、16-18、23-25天给药,联合紫杉醇80 mg/m2于第1、8、15天给药,每28天为一周期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phase I trial to determine the safety and efficacy of paclitaxel, sapanisertib, and serabelisib. PATIENTS AND METHODS: Patients with previously treated advanced solid tumors were eligible for this open label, cohort study of sapanisertib (TAK-228) and serabelisib (TAK-117) with weekly paclitaxel. A traditional 3 + 3 dose escalation design with 5 dosing cohorts was used. Patient reported outcomes were also evaluated. RESULTS: 19 heavily pretreated patients were enrolled (10 ovarian, 3 breast, and 6 endometrial cancers). All patients received comprehensive genomic profiling prior to enrollment. RP2D is sapanisertib 3 or 4 mg, serabelisib 200 mg on days 2-4, 9-11, 16-18 and 23-25 with paclitaxel 80 mg/m2 on days 1, 8 and 15 every 28 days. All patients in Cohort 5 required dose reductions and one patient experienced a DLT. The most frequent grade 3 or 4 adverse events were decreased WBCs (20%), nonfebrile neutropenia (12%), anemia (9%), elevated liver enzymes (4%), and hyperglycemia (11%). 3 patients had a CR, 4 had a PR, and 4 patients had SD > six months. ORR was 47% and CBR was 73% in 15 evaluable patients. Including all 19 enrolled patients, the PFS was 11 months and OS is still ongoing at 17 months. CONCLUSIONS: The combination of sapanisertib, serabelisib, and paclitaxel was safe and generally well tolerated. Preliminary efficacy was remarkable in an area of unmet need, especially for patient with PI3K/AKT/mTOR pathway aberrations. Positive effects and sustained clinical benefit were even seen in patients that were refractory to platinum and had failed taxane, everolimus, or temsirolimus. CLINICAL TRIAL NUMBER: ClinicalTrials.gov, NCT03154294.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Starks DC, Rojas-Espaillat L, Meissner T, et al. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors. Gynecol Oncol. 2022. PMID: 35843739. doi:10.1016/j.ygyno.2022.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。